.jpg)
The Drug (Prices Control) Order implemented in May last year brought into its purview 652 packs of 348 formulations.
The company did not respond to specific queries on the project's expansion.
Jaipuria has not specified the amount he is looking to raise, but says this is the right time to tap the capital markets.
The oralcare major has kept its ears firmly to the ground, pushing products into the hinterland and is holding fort in urban India with innovation for continued volume growth.
This comes in the wake of allegations of financial irregularities by the erstwhile management led by Harish Moolchandani.
Top companies added employees at 3% CAGR from 2003-04 to 2013-14, while revenues grew at 18%.
Growth in cities has lagged villages as consumers troubled by persistently high inflation have cut spending in the past two years.
However, international fast-food chains have had to change this business model completely, to adapt to Indian preferences.
As far as Saffola is concerned, oil and oats have been successful segments.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
Indian consumer durable market faces competition from Korean dealers.
The heat wave that began a few weeks ago as well as the prediction of a possible El Nino weather phenomenon this year has beverage and ice-cream makers hope for a 15-20 per cent growth in sales in May
Improve speed of delivery, introduce smaller packs, create greater value
Indian telecom seems to be getting back on its feet.
BSE has brought in the new technology from Deutsche Bourse.
The move to launch two new premium products back-to-back is significant since it marks the first attempt by Amul to trade up its portfolio.
Components manufactured in India are low-value products like casing and box packaging that constitute 5% of the bill for materials required in phone manufacturing.
Experts say despite it being a global deal, the transaction will have to undergo CCI scrutiny because of the scale of operations.
On Tuesday, Novartis agreed to buy GSK's oncology products business for $14.5 billion, while selling its vaccines business, excluding flu, to GSK for $7.1 billion.
ICAI has also imposed a fine of Rs 5 lakh on each of the three accused in Satyam case.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances